350 related articles for article (PubMed ID: 31280421)
1. Cell signaling and cancer: a mechanistic insight into drug resistance.
Panda M; Biswal BK
Mol Biol Rep; 2019 Oct; 46(5):5645-5659. PubMed ID: 31280421
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression.
Deng J; Bai X; Feng X; Ni J; Beretov J; Graham P; Li Y
BMC Cancer; 2019 Jun; 19(1):618. PubMed ID: 31234823
[TBL] [Abstract][Full Text] [Related]
3. Cetyltrimethylammonium Bromide Attenuates the Mesenchymal Characteristics of Hypopharyngeal Squamous Cell Carcinoma Through Inhibiting the EGFR/PI3K/AKT Signaling Pathway.
Wu TK; Ou YC; Chen YP; Huang FM; Pan YR; Lee CJ
Anticancer Res; 2021 Aug; 41(8):3789-3799. PubMed ID: 34281838
[TBL] [Abstract][Full Text] [Related]
4. Inflammatory interferon activates HIF-1α-mediated epithelial-to-mesenchymal transition via PI3K/AKT/mTOR pathway.
Yeh YH; Hsiao HF; Yeh YC; Chen TW; Li TK
J Exp Clin Cancer Res; 2018 Mar; 37(1):70. PubMed ID: 29587825
[TBL] [Abstract][Full Text] [Related]
5. PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives.
Asati V; Mahapatra DK; Bharti SK
Eur J Med Chem; 2016 Feb; 109():314-41. PubMed ID: 26807863
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways.
McCubrey JA; Steelman LS; Kempf CR; Chappell WH; Abrams SL; Stivala F; Malaponte G; Nicoletti F; Libra M; Bäsecke J; Maksimovic-Ivanic D; Mijatovic S; Montalto G; Cervello M; Cocco L; Martelli AM
J Cell Physiol; 2011 Nov; 226(11):2762-81. PubMed ID: 21302297
[TBL] [Abstract][Full Text] [Related]
7. Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway.
Chen D; Lin X; Zhang C; Liu Z; Chen Z; Li Z; Wang J; Li B; Hu Y; Dong B; Shen L; Ji J; Gao J; Zhang X
Cell Death Dis; 2018 Jan; 9(2):123. PubMed ID: 29374144
[TBL] [Abstract][Full Text] [Related]
8. Danusertib Induces Apoptosis, Cell Cycle Arrest, and Autophagy but Inhibits Epithelial to Mesenchymal Transition Involving PI3K/Akt/mTOR Signaling Pathway in Human Ovarian Cancer Cells.
Zi D; Zhou ZW; Yang YJ; Huang L; Zhou ZL; He SM; He ZX; Zhou SF
Int J Mol Sci; 2015 Nov; 16(11):27228-51. PubMed ID: 26580601
[TBL] [Abstract][Full Text] [Related]
9. Afatinib resistance in non-small cell lung cancer involves the PI3K/AKT and MAPK/ERK signalling pathways and epithelial-to-mesenchymal transition.
Coco S; Truini A; Alama A; Dal Bello MG; Venè R; Garuti A; Carminati E; Rijavec E; Genova C; Barletta G; Sini C; Ballestrero A; Boccardo F; Grossi F
Target Oncol; 2015 Sep; 10(3):393-404. PubMed ID: 25341405
[TBL] [Abstract][Full Text] [Related]
10. Extracellular vesicles shed from gefitinib-resistant nonsmall cell lung cancer regulate the tumor microenvironment.
Choi DY; You S; Jung JH; Lee JC; Rho JK; Lee KY; Freeman MR; Kim KP; Kim J
Proteomics; 2014 Aug; 14(16):1845-56. PubMed ID: 24946052
[TBL] [Abstract][Full Text] [Related]
11. Tumour microenvironment and aberrant signaling pathways in cisplatin resistance and strategies to overcome in oral cancer.
Biswal S; Panda M; Sahoo RK; Tripathi SK; Biswal BK
Arch Oral Biol; 2023 Jul; 151():105697. PubMed ID: 37079976
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
Tsurutani J; West KA; Sayyah J; Gills JJ; Dennis PA
Cancer Res; 2005 Sep; 65(18):8423-32. PubMed ID: 16166321
[TBL] [Abstract][Full Text] [Related]
13. Targeting autophagy to overcome drug resistance in cancer therapy.
Kumar A; Singh UK; Chaudhary A
Future Med Chem; 2015 Aug; 7(12):1535-42. PubMed ID: 26334206
[TBL] [Abstract][Full Text] [Related]
14. Alisertib induces cell cycle arrest and autophagy and suppresses epithelial-to-mesenchymal transition involving PI3K/Akt/mTOR and sirtuin 1-mediated signaling pathways in human pancreatic cancer cells.
Wang F; Li H; Yan XG; Zhou ZW; Yi ZG; He ZX; Pan ST; Yang YX; Wang ZZ; Zhang X; Yang T; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():575-601. PubMed ID: 25632225
[TBL] [Abstract][Full Text] [Related]
15. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
[TBL] [Abstract][Full Text] [Related]
16. Natural Products in Preventing Tumor Drug Resistance and Related Signaling Pathways.
Yang C; Mai Z; Liu C; Yin S; Cai Y; Xia C
Molecules; 2022 May; 27(11):. PubMed ID: 35684449
[TBL] [Abstract][Full Text] [Related]
17. Association of the Epithelial-Mesenchymal Transition (EMT) with Cisplatin Resistance.
Ashrafizadeh M; Zarrabi A; Hushmandi K; Kalantari M; Mohammadinejad R; Javaheri T; Sethi G
Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32503307
[TBL] [Abstract][Full Text] [Related]
18. Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells.
Dong J; Zhai B; Sun W; Hu F; Cheng H; Xu J
PLoS One; 2017; 12(9):e0185088. PubMed ID: 28934275
[TBL] [Abstract][Full Text] [Related]
19. [Tumor microenvironment elicits primary resistance to afatinib through HGF secretion].
Kang XH; Wang LF; Cao F; Fan FT; Xu ZY
Zhonghua Zhong Liu Za Zhi; 2013 Oct; 35(10):732-6. PubMed ID: 24378092
[TBL] [Abstract][Full Text] [Related]
20. Crosstalk between hedgehog and other signaling pathways as a basis for combination therapies in cancer.
Brechbiel J; Miller-Moslin K; Adjei AA
Cancer Treat Rev; 2014 Jul; 40(6):750-9. PubMed ID: 24613036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]